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Hemostasis requires conversion of fibrinogen to fibrin fibers that generate a characteristic
network, interact with blood cells, and initiate tissue repair. The fibrin network is porous and
highly permeable, but the spatial arrangement of the external clot face is unknown. Here we
show that fibrin transitioned to the blood-air interface through Langmuir film formation,
producing a protective film confining clots in human and mouse models. We demonstrated
that only fibrin is required for formation of the film, and that it occurred in vitro and in vivo.
The fibrin film connected to the underlying clot network through tethering fibers. It was
digested by plasmin, and formation of the film was prevented with surfactants. Functionally,
the film retained blood cells and protected against penetration by bacterial pathogens in a
murine model of dermal infection. Our data show a remarkable aspect of blood clotting in
which fibrin forms a protective film covering the external surface of the clot, defending the
organism against microbial invasion.
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Introduction
Hemostasis is a pivotal mechanism to prevent life-threatening blood 
loss from sites of injury, and involves close interplay between coagu-
lation and platelets. The resulting blood clot contains activated plate-
lets, red blood cells, and fibrin polymer, which holds the clot togeth-
er. Fibrin is formed by limited proteolysis of fibrinogen by thrombin. 
Thrombin cleaves small peptidic sequences from the N-termini of 
the Aα- and Bβ-polypeptides, exposing interaction sites for binding 
pockets in the C-terminal domains of the β- and γ-chains, respective-
ly (1). Fibrin thus polymerizes into protofibrils, which aggregate lat-
erally into fibers. The fibers branch and produce a 3D network with 
remarkable elastic properties (2). The structure of the fibrin network 
is determined by fiber diameter, protofibril packing, and pore size, 
the latter of which is sufficient for the incorporation of cells. Dense 
networks with thin fibers and increased rigidity are associated with 
increased risk of thrombosis, while loose clot networks with thick 
fibers and reduced rigidity are associated with bleeding (1, 3, 4).
A major conundrum after decades of fibrin polymer research 
is that fibrin fibers in blood clots appear endless, with little evi-
dence of fiber ends (Supplemental Figure 1; supplemental mate-
rial available online with this article; https://doi.org/10.1172/
JCI98734DS1). Thus, the mechanisms and structures that deter-
mine the external boundary of an extravascular (hemostatic) 
blood clot are unknown. What happens to the fibrin network and 
fibers when they reach the peripheral, exposed surface of the clot? 
Do the fibers just stop, flatten, or bend, or is the surface lined by 
platelets, red blood cells, or other cells? The architecture of this 
interface is important because it forms a distinction between host 
and the environment. To explore this, we investigated the struc-
tural characteristics of the exterior face of the blood clot and found 
that fibrin at the blood-air interface is not arranged in the form of 
fibers, but instead transitions to a continuous sheet that covers the 
clot surface. This sheet arises through Langmuir film formation, 
provides a natural limit to clot growth, prevents blood cell loss, 
and protects from bacterial infection. These data reveal a critical 
role for fibrin in hemostasis through the generation of a previously 
unrecognized bioprotective film that encapsulates the clot in the 
early stages of tissue repair.
Results
Film forms at the air-liquid interface. Our study was motivated by 
observations from scanning electron microscopy (SEM) reveal-
ing a thin film on the surface of clots where, prior to dehydration, 
the air-liquid interface had been. This film was present in clots 
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several hundred nanomoles (tens of units per milliliter) (5, 6). 
However, fibrin formation occurs at just 2–3 nM thrombin (0.2–
0.3 U/ml), before the vast majority of thrombin has been gen-
erated (7). Our data indicate that the film forms most optimally 
at lower thrombin concentrations, which led to longer clotting 
times, allowing more fibrin to accumulate at the surface before 
the underlying network has formed. Previous data showed that 
lower thrombin concentrations are also optimal for maximum 
protofibril packing in fibrin fibers (8).
CaCl2 concentration (5, 10, 20 mM) had no effect on film 
formation (Figure 2H and Supplemental Figure 3C), but the 
absence of CaCl2 resulted in at least a 1.9-fold decrease in MSF 
and 1.5-fold decrease in film thickness. This indicates that film 
formation is not dependent on CaCl2 concentration but absence 
of CaCl2 dramatically reduces its formation.
Film formation occurred at all fibrinogen concentrations test-
ed (0.05, 0.5, 1, 2.5 mg/ml; Figure 2I and Supplemental Figure 
3D), even when the fibrinogen levels were not sufficient to form a 
clot that filled the whole volume of the liquid (Supplemental Fig-
ure 3E). Interestingly, as fibrinogen levels increased up to 1 mg/
ml, MSF and film thickness decreased in a stepwise manner, sig-
nifying a decrease in film formation. Increases in fibrinogen con-
centration lead to shorter lag times and faster clotting rates (9). So 
in a trend similar to that for thrombin concentrations, a shorter 
lag time led to less fibrin accumulating at the air-liquid interface, 
leading to thinner films.
We also investigated film formation in samples from patients 
with dysfibrinogenemia and afibrinogenemia. To prevent chang-
es in the clot or film structure with the addition of normal fluo-
rescently labeled fibrinogen, we fluorescently labeled a non- 
antibody-binding protein (Affimer) (10) specific to fibrinogen 
with Alexa Fluor 488. This was added to the patient plasma before 
clotting, where it bound to any fibrinogen within the plasma. A 
clot was then formed and imaged using LSCM (Supplemental Fig-
ure 3F). Samples from patients with dysfibrinogenemia formed a 
film that had slightly higher MSF and thickness than clots formed 
from normal pool plasma. Afibrinogenemia patient samples did 
not form a fibrin clot or film, as expected (Figure 2J).
formed from human whole blood or platelet-poor plasma (PPP) 
when clotting was initiated with thrombin (0.5 U/ml; Figure 1, A 
and B) or tissue factor (5 pM; Supplemental Figure 2, A and B). 
Using laser scanning confocal microscopy (LSCM), we found the 
film was also present in clots from whole blood (thrombin, Figure 
1C; tissue factor, Supplemental Figure 2C) and plasma (thrombin, 
Figure 1D; tissue factor, Supplemental Figure 2D) in fully hydrat-
ed conditions. When single slices of a clot in the z-plane were 
imaged using LSCM, the film appeared continuous around the 
clot exterior (Figure 1E).
Film is composed of fibrin. Fluorescence detected in the LSCM 
images indicated that fibrinogen or fibrin was present in the film 
(Figure 1, C–E). To better characterize the film components, we 
peeled it away from the surface of plasma clots (Figure 2A) formed 
with or without T101 (transglutaminase inhibitor). The films were 
reduced and subjected to SDS-PAGE (Figure 2B). The film con-
tained fibrin, and this was confirmed by Western blotting with a 
polyclonal antibody against fibrinogen (Supplemental Figure 3A).
To assess whether the film could form from fibrin alone, we 
formed clots from purified fibrinogen (1 mg/ml) and throm-
bin (0.5 U/ml) and examined them using SEM and LSCM. We 
observed formation of films that mimicked those formed on whole 
blood and plasma clots (Figure 2, C and D). Films transitioned to 
fibers in places (Figure 2E) and connected to the fibrin network 
through tethering fibers (Figure 2F). These observations show that 
fibrin(ogen) alone is capable of producing a film at the clot surface.
We next investigated how other plasma components influ-
enced film formation. Purified fibrinogen was spiked with Alexa 
Fluor 488–fibrinogen (25 μg/ml), and different clotting conditions 
were tested. Film mean sheet fluorescence (MSF) and film thick-
ness were measured to quantify changes (Supplemental Table 1).
The film formed at all thrombin concentrations (0.1, 0.5, 1, 
10 U/ml; Figure 2G and Supplemental Figure 3B). However, as 
the thrombin concentration increased, the MSF and thickness of 
the film decreased in a stepwise manner, indicating a reduction 
in the quantity of fibrin present. Thrombin generation triggered 
by tissue factor in plasma starts slowly after a short lag phase, 
and then its concentration rapidly increases to a maximum of 
Figure 1. Film forms on the clot surface at the air-liquid inter-
face. (A and B) SEM of film formed at the air-liquid interface in 
whole blood and plasma clots. At places where the film is torn 
(due to SEM sample processing procedures), red blood cells 
(asterisk), platelets (thick arrow), and fibrin (thin arrow) are 
observed in whole blood clots (A), and fibrin (asterisk) in plasma 
clots (B). Red blood cells are also visible through the film in 
whole blood clots. (C and D) LSCM of film formed at the air-liquid 
interface in whole blood and plasma clots. Fibrinogen was 
fluorescently labeled with Alexa Fluor 488 (green) or Alexa Fluor 
594 (red). Under fully hydrated conditions of LSCM, tears in the 
film were not observed. (E) LSCM of a single Z-plane slice of a 
plasma clot showing continuous film around the clot. The central 
gap in the clot image is where the pipette was introduced into 
the plasma drop to inject thrombin. Images represent findings 
reproduced in at least n = 3 experiments. Scale bars: A and B, 10 
μm; C and D, 50 μm; E, 1 mm. All images are representative of n 
= 3 experiments.
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The role of platelets in film formation was investigated by 
comparing film formation in PPP and platelet-rich plasma (PRP). 
The lack of difference in MSF and film thickness between PPP and 
PRP indicates that platelets do not influence film formation (Fig-
ure 2N and Supplemental Figure 3J).
To investigate whether fibrinogen structural elements are 
essential for film formation, we tested natural and recom-
binant fibrinogen variants: γA/γA, the common fibrinogen 
isoform; γA/γ′, a heterodimeric splice variant that adds nega-
tive charge to the C-terminus of the γ-chain (11); γ3x, a triple 
γ-chain mutant that eliminates all γ-chain crosslinking (12); 
α220, in which the α-chain is truncated after residue Ser220, 
removing the connector and C-terminal globular domain of the 
αC-region; and α390, in which the α-chain is truncated after 
residue Asp390, removing the C-terminal globular domain. 
Clots formed with each of these variants produced fibrin films 
(Figure 2, O–Q, and Supplemental Figure 4, A–C). Differences 
Films were similar in clots produced with reptilase (2.4 U/
ml), which only cleaves fibrinopeptide A (and not fibrinopeptide 
B) from fibrinogen, and thrombin (Figure 2K and Supplemental 
Figure 3G). This demonstrates that film formation occurs during 
fibrinogen-to-fibrin conversion, regardless of the activating prote-
ase and independent of fibrinopeptide B (FpB) release.
We also assessed the effect of temperature on film formation 
(21°C room temperature, 31.5°C skin temperature, 37°C core body 
temperature). Although films formed at all 3 temperatures, film 
formation increased at least 20%–30% at 31.5°C compared with 
room temperature or core body temperature (Figure 2L and Sup-
plemental Figure 3H). Enhanced film formation at skin tempera-
ture is consistent with a physiological role for fibrin films in cuta-
neous wounds and dermal injuries.
There were no differences in film MSF or thickness with or 
without factor XIII (FXIII) (3.7 μg/ml; Figure 2M and Supplemental 
Figure 3I), showing that FXIII is not necessary for film formation.
Figure 2. Film only requires fibrin for formation. (A) The film was peeled from clots using a needle. (B) Films removed from clots produced with or without 
T101 were run alongside FXIII, BSA, purified fibrin, and purified fibrinogen (Fgn) on reducing SDS-PAGE. MW, molecular weight marker. (C) SEM of the film in a 
clot produced from purified fibrinogen. A tear in the film exposes the underlying clot, as was often observed in SEM. Scale bar: 10 μm. (D) LSCM of the film at 
the air-liquid interface of a clot produced from purified fibrinogen, without breaks in fully hydrated conditions. Fibrinogen fluorescently labeled with Alexa Fluor 
488. Scale bar: 50 μm. (E) SEM image of areas of film transitioning into fibers. Scale bar: 1 μm. (F) LSCM of tethering fibers connected to the film. Scale bar: 50 
μm. Images in A–F are representative of n = 3 experiments. (G–Q) Mean sheet fluorescence (MSF) measurements of the film comparing different conditions: (G) 
thrombin concentration, n = 4 experiments; (H) CaCl2 concentration, n = 4 experiments; (I) fibrinogen concentration, n = 6 experiments; (J) normal pool (NP; n = 3 
patients) versus dysfibrinogenemia (Dysfib, n = 2 patients) and afibrinogenemia (Afib, n = 3 patients); (K) thrombin versus reptilase, n = 4 experiments; (L) tem-
perature, n = 4 experiments; (M) FXIII, n = 4 experiments; (N) PPP versus PRP, n = 6 individuals; (O) γA/γA fibrinogen versus γA/γ′ fibrinogen, n = 6 experiments; 
(P) fibrinogen triple γ-chain crosslinking mutant (3xγ), n = 6 experiments; (Q) fibrinogen α-chain deletion mutants (α390 and α220), n = 6 experiments. Asterisks 
indicate difference from first column; crosses, difference between other columns. *P < 0.05; **P < 0.01, ††P < 0.01; †††P < 0.001; ****P < 0.0001, ††††P < 0.0001. 
Mean ± SD. Unpaired t test (2 groups); ANOVA (multiple groups).See Supplemental Table 1 for estimated corresponding film thicknesses.
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ing fibers (Figure 2F) indicated that a specific biophysical mecha-
nism governs fibrin film formation. To identify this mechanism, 
we used LSCM to visualize film formation and breakdown in plas-
ma and purified fibrinogen solutions. Clot formation was initiated 
with thrombin (0.5 U/ml) in plasma (Figure 3A and Supplemental 
Video 1) or purified fibrinogen (Supplemental Figure 4D and Sup-
plemental Video 2), and with tissue factor (5 pM) in plasma (Sup-
plemental Figure 4E and Supplemental Video 3). Fibrin accumu-
lated at the surface, forming a film before — or at approximately 
the same rate as — the fibrin fibers underneath the film that consti-
tute the clot network. Once the clot was fully formed, breakdown 
in MSF were attributable to differences in polymerization rates 
and fibrin clot structure (13). These data indicate that neither 
the C-terminal domain of the γ-chain, the α-chain C-terminal 
connector region, nor the α-chain C-terminal globular domain 
is required for film formation.
Collectively, these findings show that fibrin produces a film 
that covers the blood clot at the air-liquid interface, and although 
other factors modulate film thickness or the amount of fibrin in 
the film, only fibrin is required.
Mechanism of film formation. The transition of film to fibers 
(Figure 2E) and connection of film to the clot network via tether-
Figure 3. Mechanism of fibrin film formation. (A) Stills from videos of fibrin film formation over time in plasma when clotting was initiated with thrombin 
(n = 3 experiments). Scale bar: 50 μm. (B) Stills from videos of film lysis by tPA in plasma (n = 3 experiments). Scale bars: 50 μm. (C) Changes in surface 
pressure (SP) in the Langmuir-Blodgett trough with different fibrinogen or fibrin concentrations over time. Insets show early time points (0–15 minutes). 
Data are shown as mean ± SD, n = 3 experiments. SP, surface pressure. (D) Maximum Langmuir-Blodgett trough surface pressure of fibrinogen and fibrin 
with increasing concentrations. Data are shown as mean ± SD; **P < 0.01, ****P < 0.0001; n = 3 experiments; 2-way ANOVA, F = 293.5, degrees of freedom 
[df] = 1, P < 0.0001. (E) SEM images of the interior and exterior surfaces of films peeled away from plasma clots. Note differences in scale bars: interior, 3 
μm; exterior, left 500 nm, right 50 nm. (F) Accumulation of MSF of clots from purified fibrinogen over time analyzed by LSCM. Data are shown as mean ± SD. 
(G) Maximum MSF, n = 3 experiments, F = 330.7, df = 2, P < 0.0001; time to maximum MSF, n = 3 experiments, F = 0.1875, df = 2, P = 0.8337; maximum rate 
of MSF increase, n = 3 experiments, F = 20.55, df = 2, P = 0.0021 as analyzed by LSCM. Data are shown as mean ± SD; *P < 0.05, **P < 0.01, ****P < 0.0001 
compared with fibrinogen. (H) LSCM image of the air-liquid interface of a plasma clot formed in the presence of Tween-20 (0.1%), eliminating the film cover-
ing the clot. Yellow line represents the location of the air-liquid interface. Image is representative of n = 3 experiments. Scale bar: 50 μm. IIa, thrombin.
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The addition of more than 30 × 1013 molecules of fibrinogen did 
not further increase maximum pressure (100 × 1013 and 5,312 × 1013 
molecules [1 mg/ml]), indicating that 30 × 1013 (0.006 mg/ml) is 
the maximum amount of fibrin/fibrinogen that can be accommo-
dated at the surface. This was much lower than physiological fibrin-
ogen levels (2–4 mg/ml). From this we calculated that this would 
allow for approximately 34 nm2 per fibrin/fibrinogen molecule. 
Assuming a fibrin(ogen) D-region is approximately 6.5–6.7 nm 
and the E-region is approximately 5–5.3 nm in diameter (20, 21), 
the half-staggered fibrin model (22) would allow for approximately 
31–34 nm2 per fibrin/fibrinogen molecule, in close agreement with 
our experimental data. This indicates that fibrin/fibrinogen mole-
cules are tightly packed and are positioned perpendicularly to the 
air-liquid interface.
In order to investigate the morphology of the film below the 
surface, we compared the interior and the exterior surfaces using 
SEM. The film was peeled away from the exterior of the clot and 
stretched over a coverslip with either the interior or exterior sur-
face exposed (Figure 3E). The exterior surface was smooth, some-
times with very small pores (~24.8 ± 8.8 nm pores, yellow arrows) 
or with small nodes (~6.4 ± 0.9 nm domains, yellow circles). In 
contrast, the interior surface was rough, with holes, pores, and a 
fibrous structure, more closely resembling the clot network. In 
agreement with the Langmuir-Blodgett trough data, these data 
imply that fibrin films have an ordered, dense structure at the sur-
face but become less ordered deeper in the film, where they tran-
sition into more fibrous structures.
With the interior surface looking similar to a clot network, 
we hypothesized that fibrin polymerization was involved in 
film formation. To assess this, we followed the accumulation of 
fibrin/fibrinogen below the surface and analyzed the effects of 
polymerization over time using LSCM. Time courses of polym-
erizing fibrin, fibrin monomers, or fibrinogen alone spiked with 
Alexa Fluor 488–fibrinogen were followed in a purified (1 mg/ml 
fibrinogen/fibrin) or plasma system (2× dilution). Accumulation 
was quantified by MSF (Figure 3, F and G). Purified fibrinogen 
accumulated at the air-liquid surface with a maximum rate of 
0.26 ± 0.03 MSF/min, reaching maximum fluorescence (5.5 ± 
1.3 MSF) after 57.3 ± 2.1 minutes. Fibrin monomers had a max-
imum rate approximately 3-fold faster than that of fibrinogen 
(0.8 ± 0.8 MSF/min), with twice as much protein accumulating 
at the surface (maximum MSF, 10.4 ± 0.8) after 58 ± 1.5 minutes. 
Polymerizing fibrin accumulated at the surface at the greatest 
rate, with a maximum increase in fluorescence of 1.46 ± 0.39/
min, more than 5-fold the rate of fibrinogen. It reached a maxi-
mum fluorescence (27.1 ± 1.1 MSF) after 59 ± 0.7 minutes (Figure 
3, F and G, Supplemental Figure 5A, Supplemental Table 4, and 
Supplemental Videos 2, 6, and 7). The same pattern was seen 
in plasma, with polymerizing fibrin accumulating at the surface 
more quickly than fibrin monomers and fibrinogen (Supple-
mental Figure 5, B–D, Supplemental Table 4, and Supplemen-
tal Videos 1, 8, and 9). This indicates that fibrin polymerization 
contributes to film formation by enhancing the accumulation 
of fibrin at the air-liquid interface. This effect is likely due to 
a combination of stronger interactions between the molecules 
of fibrin versus fibrinogen and an increase in hydrophobicity of 
fibrin (1, 23), which retains fibrin at the surface.
was initiated with tissue plasminogen activator (tPA; 85 ng/ml) in 
plasma clots, or tPA plus plasminogen (25 μg/ml) in purified sys-
tems, and observed over time (plasma, Figure 3B and Supplemen-
tal Video 4; purified, Supplemental Figure 4F and Supplemental 
Video 5). In both cases, the films lysed at approximately the same 
rate as the network of fibrin fibers.
We next investigated accumulation of fibrinogen and fibrin at 
the air-liquid interface using a Langmuir-Blodgett trough, which 
analyzes monolayer film formation of amphiphilic molecules at the 
air-liquid interface (14, 15). Few previous studies have investigated 
fibrinogen at the air-liquid interface (16–19), and to our knowledge 
none have examined fibrin. Purified fibrinogen or fibrin monomers 
(fibrinogen with or without 1 U/ml thrombin and 5 mM Gly-Pro-
Arg-Pro peptide [GPRP]) were injected into the subphase of the 
trough at increasing quantities (1 × 1013 to 5,312 × 1013) molecules 
of fibrinogen/fibrin), and surface pressure measurements were 
recorded over time. As protein accumulated at the surface over 
time, surface pressure increased and then at a maximum pressure 
(Figure 3C). At 1 × 1013 molecules, neither fibrin nor fibrinogen cov-
ered the surface, so there was no increase in surface pressure. At 5 × 
1013 and 20 × 1013 molecules of fibrinogen/fibrin, there was a delay 
before fibrinogen or fibrin resulted in an increase in surface pres-
sure. But greater quantities (30 × 1013 and 100 × 1013 molecules) of 
fibrinogen and fibrin caused an increase in surface pressure almost 
instantaneously (Figure 3C, insets, and Supplemental Table 2). 
Maximum surface pressure escalated with increasing amounts of 
fibrinogen and fibrin (Figure 3, C and D, and Supplemental Table 
3). Fibrin resulted in significantly lower surface pressure levels than 
fibrinogen at 5 × 1013 and 20 × 1013 molecules, but as the quantity of 
fibrinogen/fibrin increased, these differences were no longer seen. 
Figure 4. A model of fibrin film forming at the clot surface. (A) Proposed 
2D model of fibrin(ogen) rising to the air-liquid interface and accumulating 
into a multilayer film with half-staggered fibrin molecules and tethering 
protofibrils (beginning of fibrin fibers). (B) Side-on view of a 3D model of 
the fibrin film with half-staggered fibrin molecules. D-regions are repre-
sented by 6.7-nm-diameter blue spheres; E-regions are represented by 
5.3-nm diameter red spheres; and the connecting α-, β-, and γ-chains are 
represented by orange cylinders. The translucent box represents the liquid 
at the air-liquid interface (C) Top view of the 3D fibrin film model.
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We next investigated film strength using atomic force micros-
copy (AFM). Young’s modulus was calculated for plasma samples 
with and without transglutaminase inhibitor T101 by fitting a 
Sneddon model for conical tips to all force curves found over the 
entire area that was imaged (Supplemental Figure 6, A and B). 
Fibrin fibers were visible under the film surface, and the Young’s 
modulus for these areas indicated greater stiffness than in places 
suspended between fibers. To find the stiffness of the film alone, 
we determined Young’s modulus by measuring areas between 
the underlying fibers of clots formed from plasma. The aver-
age Young’s modulus of the film was approximately 3-fold lower 
than in regions supported by fibers (suspended, 7.65 ± 0.24 kPa 
vs. fiber, 21.79 ± 2.79 kPa; P = 0.0001). Inhibition of cross-link-
ing decreased the modulus of the suspended film further by just 
over 10-fold to 0.72 ± 0.14 kPa, which is slightly more than the 
decrease in fibrin stiffness previously reported in whole clots and 
single fibers (2- to 8.5-fold) (24–27). Areas supported by fibrin 
fibers decreased just over 4-fold to 5.1 ± 0.75 kPa in the absence 
of cross-linking (Supplemental Figure 6C). As a consequence, 
although fibrin crosslinking was not required for film formation 
(Figure 2L), it increased film elastic modulus.
Given that fibrin accumulates at the air-liquid interface, we 
hypothesized that film formation should be preventable by block-
ing the air interface with surfactant molecules. Accordingly, addi-
tion of Tween-20 (0.1%) prevented film formation and resulted in 
a dense, partly collapsed clot, probably due to the loss of surface 
tension (Figure 3H). Furthermore, blocking the air-liquid interface 
using mineral oil or petroleum jelly also prevented film formation 
(Supplemental Figure 6D).
Based on the Langmuir (Figure 3, C and D) and accumulation 
data (Figure 3, F and G), we propose a model (Figure 4A) where-
by, upon injury and exposure to air, fibrinogen molecules in the 
blood are rapidly adsorbed to the air-exposed surface, forming an 
organized monolayer at the air-liquid interface. Simultaneously, 
tissue factor stimulates fibrinogen cleavage via thrombin, leading 
to fibrin formation. Fibrin(ogen) continues to rise and accumu-
late at the air-liquid interface, packing in more molecules. At the 
same time fibrin begins to fit together in a half-staggered forma-
tion, allowing for the buildup of multiple layers of fibrin through 
A-a knob-hole interactions and the formation of tethering fibers 
(Figure 4, A–C). This leads to production of a dense layer of fibrin 
across the surface of the clot.
Protection against microbes. In view of the rapid formation 
of the fibrin film after exposure to an air interface, we hypothe-
sized that an important physiological role of the film is to form an 
immediate barrier to protect the vascular breach against microbi-
al invasion until white blood cells are recruited to the wound site 
(28). To investigate this hypothesis, we used a Boyden chamber to 
analyze migration of 3 types of bacteria commonly found in the 
natural skin flora (Escherichia coli, Staphylococcus epidermidis, and 
Staphylococcus aureus) through clots (Figure 5A). Bacteria were 
grown to 3.6 × 108 to 8.5 × 108 cells/ml, fluorescently labeled with 
BacLight green, and applied to the external surface of 3 types of 
clots: (a) clots formed with 0.1% Tween-20 to prevent film forma-
tion, (b) clots where the surface was perforated with a needle to 
make holes in the film, and (c) normal clots with intact film. Flu-
orescent bacteria that moved through the clots were quantified 
over 48 hours (Figure 5B and Supplemental Figure 7A). The time 
taken for the first bacteria to break through the clots was defined 
as when fluorescence became greater than 2% of the total added 
fluorescent bacteria. No fluorescent bacteria migrated through the 
clots within the first 8 hours. E. coli migrated through the perforat-
ed (11.3 ± 1.2 hours) and Tween-20–treated clots (25.3 ± 1.2 hours) 
significantly faster than normal clots (38.0 ± 7.2 hours) (Figure 5C; 
P = 0.0008). A similar trend was seen with the 2 other bacteria 
(Supplemental Figure 7B). After the initial breakthrough, the rate 
of bacteria migration was comparable among clot types. This sug-
gests the film prevents bacterial infiltration into the site of injury 
for at least 12–27 hours, allowing time for white blood cell recruit-
ment and the underlying clot to fully form.
Fibrin film formation in vivo and blood cell retention. To inves-
tigate the role of the film on bacteria migration in vivo, we estab-
lished a murine dermal injury model. Initially, we investigated 
whether fibrin film formation occurred ex vivo in mouse blood. 
Clots were formed with whole blood from WT or fibrinogen-de-
ficient mice and were prepared for SEM. Blood from WT mice 
formed a fibrin film at the air-liquid interface, whereas blood from 
fibrinogen- deficient mice did not (Supplemental Figure 8A). We 
next established a murine dermal injury model in which a 2-mm 
puncture was created in the skin on the back or abdomen of anes-
Figure 5. Fibrin film slows bacteria movement through clot. (A) Diagram-
matic representation of the bacteria clot migration assay in the Boyden 
chamber. Bacteria moved from the 50% nutrient broth through the fibrin 
film (if present), into the fibrin clot, and then into the superoptimal broth 
with 20 mM glucose (SOC) medium. Quantity of bacteria moving through 
the clot over time was analyzed by fluorescence in the SOC media. (B) 
Movement of fluorescently labeled E. coli bacteria through the clots (dis-
played as quantity of fluorescent bacteria breaking through the clot as a 
percentage of fluorescent bacteria added) with 3 different film conditions: 
normal, perforated, and removal with Tween-20. Bac, bacteria. (C) Time 
taken for the first fluorescently labeled E. coli bacteria to break through 
the clot. *P < 0.05, ***P < 0.001 compared with normal clot; n = 3 experi-
ments; 1-way ANOVA, F = 29.29, df = 2, P = 0.0008.
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thetized mice. The injury was either left uncovered to allow clotting 
exposed to the air or immediately covered with a thin layer of oil to 
remove the air-liquid interface, which was washed off with saline 
once the clot had formed. After 60 minutes, clots and surrounding 
skin were surgically removed, processed, and imaged by SEM (Fig-
ure 6A). In the untreated control section, a film was present on the 
exterior surface of clots. Consistent with the in vitro experiments, 
oil treatment prevented film formation, leaving the fibrous fibrin 
network exposed and clearly visible by SEM (Figure 6A). Some 
of these clots were embedded in paraffin, sectioned, and stained 
using Martius, Scarlet, and Blue (MSB) or were probed with a 
fibrin-specific antibody (59D8). In the untreated control sections, 
the film can be seen along the surface of the clot, as a thin pink layer 
with MSB (Figure 6B) or a thin brown layer with 59D8, confirming 
that fibrin makes up the film in vivo (Supplemental Figure 8B). In 
clots treated with oil, the film was not present. This showed that 
the oil prevented film formation in vivo and could be used to assess 
bacterial migration and proliferation in clots without a film.
During the establishment of our in vivo model, we found his-
tology sections of clots formed in the presence of oil — and there-
fore lacking the film — showing regions of loose cells that were not 
retained within the clot (Figure 6C). In micrographs of the control 
clots, we found erythrocytes pushed against the inside of the film 
(Figure 6D). These findings suggested that the fibrin film helps to 
prevent leakage of blood cells from dermal lesions. To investigate 
this, we formed clots from whole blood with no intervention, in 
the presence of Tween-20 (0.1%), or with the film being perforat-
ed after 1 hour. After 2 hours the amount of hemoglobin released 
from the clot was measured. We found that the quantity of hemo-
globin released was more than 12-fold greater in the Tween-20–
treated (4.37 ± 0.38 g/l) and perforated clots (4.14 ± 0.85 g/l), with 
almost no hemoglobin being released from the normal clot (0.32 
± 0.18 g/l, P = 0.0002; Figure 6E). These data show that the film 
plays a role in the retention of red blood cells within the clot.
Protective role of fibrin film in a murine dermal injury model. We 
next investigated the role of the fibrin film in protection against 
bacterial proliferation and dissemination in vivo. After the clots 
were formed as described above (with or without a layer of oil), 
2 μl bioluminescent Pseudomonas aeruginosa (4 × 105 CFU), a 
Gram-negative flagellated bacterium associated with severe hos-
pital-acquired infections and significant resistance to antibiotics, 
were deposited on the surface of the clots covering the dermal 
punctures. Mice were imaged every 4 hours using a 3D Ivis Spec-
trum In Vivo Imaging System to assess bacterial proliferation. 
Control experiments were run in parallel to demonstrate oil had 
no effect on bacterial proliferation. In the mice with an intact fibrin 
film, the bioluminescence did not increase over 12 hours, show-
ing that the bacteria did not proliferate over this period in these 
mice (Figure 7, A and B, and Supplemental Table 5). In contrast, in 
mice without a fibrin film the bioluminescence was significantly 
higher after 4 hours and increased over time up to 1.034 × 105 p/s/
cm2/sr (interquartile range [IQR], 0.470, 0.359; where “p” is pho-
tons and “sr” is steradians), compared with 0.151 × 105 p/s/cm2/
sr (IQR, 0.107, 0.371; P = 0.0005) in the mice with films (Figure 
7, A and B, and Supplemental Table 5). These data show that the 
bacteria were proliferating within the wound in the absence of 
Figure 6. Fibrin film formation in vivo. (A) Clots 
were formed in a ventral, dermal puncture injury 
model in mice and left clear or covered with a layer 
of mineral oil, fixed, dehydrated, and imaged by 
SEM. The white box represents the area of mag-
nification for the image to the right. Clots covered 
with oil showed a rough fibrous clot surface, and 
clots left untreated showed a smooth fibrin film 
covering the clot. Images are representative of n = 
4 mice. Scale bars: left, 1 mm; right, 2 μm. (B) Clots 
left clear or with a layer of oil covering the surface 
from the dermal puncture model were surgically 
removed, and cross sections were stained with 
MSB (erythrocytes in yellow, fibrin in pink). Fibrin 
film shows as continuous pink layer; clot appears 
yellow interspersed with pink. Asterisks highlight 
the air-liquid interface. Images are representative 
of n = 4 mice. (C) Clots from the murine dermal 
puncture model covered with oil showed extrusion 
of red blood cells from the clot in the absence of 
a fibrin film. Asterisk highlights extrusion of red 
blood cells from the clot. Image is representative 
of n = 4 mice. (D) Clots produced with human 
whole blood and thrombin and imaged by SEM 
demonstrated containment red blood cells by the 
fibrin film. Image is representative of n = 3 individ-
uals. Scale bar: 40 μm. (E) Hemoglobin retention 
assay in normal, perforated, and Tween-20–treated 
clots. ***P < 0.001 compared with normal clot;  
n = 3 individuals; 1-way ANOVA, F = 52.14, df = 2,  
P = 0.0002. Hb, hemoglobin.
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lates due to the conversion of fibrinogen to fibrin, and the resultant 
increase in hydrophobicity of the fibrin molecule (1, 23). The unique 
fibrin polymerization mechanisms, which involve knob-hole inter-
actions, lead to fibrin being able to produce both films and fibers 
(29), and we show that this culminates in a remarkable integrated 
clot structure that includes a fibrin film covering a network of fibers. 
This finding transforms our understanding of blood clots at injury 
sites and sheds new light on a major enigma — how the clot ends at 
the air-blood interface — that has troubled the field for a long time.
The film has previously been observed in our laboratory and 
those of others in SEM images of blood, plasma, or fibrin clots. 
However, until now, it has been overlooked, as it was alleged to be 
an artefact of sample preparation. The close association of fibrin 
clot structure with thrombosis risk (3, 30, 31) has led researchers to 
focus on areas of the clot not covered by the fibrin film, i.e., away 
from the clot-air interface, or in areas where the film may have 
ruptured during sample processing. Previous studies have shown 
that fibrin is able to produce sheet-like structures, across gaps in a 
striated substrate, for example (29), or in blood clots (32). Howev-
er, the physiological relevance of these structures and the mech-
anism of formation were not explored. Here, we investigated the 
film in detail and found it to be a physiological product of clotting 
and fibrin formation.
the film. To confirm the difference in bacteria numbers, we har-
vested and mechanically homogenized the clots and surrounding 
skin from sacrificed animals after 12 hours. Serial dilutions of the 
homogenates were plated on agar for analysis of bioluminescence 
and bacterial CFU (Figure 7, C and D). In agreement with the bio-
luminescence data, the mice that had no film on their clot showed 
a much greater number of bacteria (2.53 × 106 ± 0.298 × 106 CFU/
ml) within the wound and skin than the mice that had an intact clot 
film (0.064 × 106 ± 0.014 × 106 CFU/ml). These data demonstrate 
that the film has a protective role, slowing or preventing the pro-
liferation of bacteria and reducing the movement of bacteria into 
wounds and skin in the first 12 hours after injury.
Discussion
This study demonstrates that fibrin plays an unexpected role in 
hemostasis, producing a film that not only encapsulates the clot and 
thereby retains cells, but also functions as a protective layer at the 
interface between the clotting blood and the air, preventing micro-
bial infection. The structural characteristics of this fibrin film are 
completely different from those of the fibrin fiber network. The film 
is composed of a thin continuous layer of fibrin and is connected to 
the fibrous fibrin network through tethering fibers. Film formation 
is initiated by the exposure of blood to the air interface and accumu-
Figure 7. Fibrin film slows bacteria proliferation and dissemination in vivo. (A) Measurement of bioluminescent bacteria proliferation with or without 
film in a murine dermal injury model over time. Images are representative of n = 8 mice (B) Quantification of bioluminescent bacteria in this model.  
*P < 0.05, ***P < 0.001, n = 8 mice, Kruskal-Wallis test, Kruskal-Wallis statistic = 36.55, 6 groups, P < 0.0001. (C) Measurement of bioluminescent bacteria 
from wound and surrounding skin with and without film after 12-hour spread on agar plates. Images are representative of n = 3 mice. (D) CFU/ml of bacte-
ria from wound and surrounding skin with or without film after 12 hours. **P < 0.01, n = 3 mice, unpaired t test, t = 8.26, df = 4, P = 0.0012.
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in 50 mM Tris-HCl and 100 mM NaCl pH 7.4. The purity of the γA/γA 
and γA/γ′ preparations was checked on a NuPAGE unit with 4%–12% 
Bis-Tris gradient gels (Invitrogen), and aliquots were stored at –80°C.
Mutant fibrinogen expression. Recombinant human fibrinogen 
expression and purification have been described previously (12, 35). 
Briefly, truncations (αSer220 and αAsp390) and γ-chain mutations 
(Q398N/Q399N/K406R, referred to as γ3x) were established through 
the use of a QuikChange II Site-Directed Mutagenesis Kit (Agilent 
Technologies). The expression vector pMLP encoded the entire 
cDNA for either the α- or γ-chain. Primers were designed to change 
residues at desired locations (γ398, γ399, γ406) or to create a stop 
codon at α221 and α391. Mutations and truncations were confirmed 
by sequencing (MRC Protein Phosphorylation and Ubiquitylation Unit 
[PPU] DNA Sequencing and Services, University of Dundee, Dundee, 
United Kingdom). Plasmids were transfected into CHO cells contain-
ing the remaining fibrinogen chains. A second plasmid was transfect-
ed for selection (pMSV-his). Recombinant fibrinogen WT, γ3x, and 
α-truncations were produced in roller bottles containing microcarrier 
beads and DMEM/F12 (Thermo Fisher Scientific), and medium was 
supplemented with aprotinin, 5 μg/ml insulin, 5 μg/ml transferrin, 
and 5 ng/ml sodium selenite (Roche). Medium was collected and 
replaced every 48 hours and stored at –40°C with the addition of 150 
μM PMSF, and harvested for 8 weeks. The fibrinogen was precipitated 
overnight with 40% saturated ammonium sulfate (VWR Internation-
al) and a mixture of protein inhibitors (20 mM MES hydrate pH 5.6, 5 
mM 6-aminihexanoic acid, 5 mM benzamidine, 100 μM PMSF, 1 μM 
pepstatin, 1 μM leupeptin). The precipitated medium was centrifuged 
at 14,500 g for 45 minutes without brakes at 4°C in an Avanti J-265 XPI 
(Beckman Coulter). The pellet was resuspended in a protein cocktail 
(333 mM NaCl, 222 mM Tris, 111 μM PMSF, 5 μM pepstatin, 5 μM leu-
peptin, 1 mM EDTA, 11 U/ml trypsin inhibitor, 5 mM benzamidine, 5 
mM 6-aminihexanoic acid), incubated for 30 minutes at 4°C, and cen-
trifuged at 43,000 g for 30 minutes. Supernatant was collected and 
kept at –80°C. Samples were purified by immunoaffinity chromatog-
raphy (IF-1 mAb, 10 mg; Kamiya Biomedical) as previously described 
(35). Fractions containing fibrinogen were pooled and stored at –80°C. 
Fibrinogen was concentrated and dialyzed in 50 mM Tris-HCl and 
100 mM NaCl pH 7.4. Protein integrity was assessed by SDS-PAGE.
SEM: whole blood, plasma, purified fibrinogen, thrombin/tissue factor. 
Clots for SEM were prepared by adding 10 μl activation mixture (whole 
blood/plasma: 0.5 U/ml human thrombin or 5 pM tissue factor [Diagnos-
tica Stago], CaCl2 5 mM; purified fibrinogen: 0.5 U/ml human thrombin, 
5 mM CaCl2 final concentrations, in TBS) to 100 μl of whole blood, plas-
ma, or purified fibrinogens with or without FXIII (final concentrations: 
fibrinogen, 1 mg/ml; FXIII, 3.7 μg/ml). The clotting mixture was imme-
diately transferred to pierced Eppendorf lids. Clots were left to form in a 
humidified chamber at room temperature for 2 hours. Clots were washed 
with saline solution to remove excess salt and prepared for microscopy 
by fixation in 2% glutaraldehyde solution for at least 120 minutes. Clots 
were further washed with sodium cacodylate buffer (67 mM C2H6AsN-
aO2, pH 7.4) and dehydrated in a series of increasing acetone concentra-
tions (30%–100%). Clots were critical point dried with CO2, mounted 
onto stubs, and sputter coated with platinum using a Cressington 208 
HR (Cressington Scientific Instruments). Each clot was formed in dupli-
cate and imaged in 5 areas, at different magnifications (2,500×, 5,000×, 
10,000×, 20,000×, 25,000×, and 50,000×) using a Hitachi SU8230 
high-performance cold field emission (CFE) SEM (Chiyoda).
Fibrinogen and fibrin have previously been associated with 
protection against systemic infection (33, 34). Our new data 
demonstrate that fibrin additionally plays an important role in 
controlling local infection at injury sites, forming an instant bar-
rier that slows the proliferation of bacteria and delays its move-
ment into the wound, allowing the underlying clot to fully form 
and create a more permanent barrier. Lack of this clot barrier 
film is expected to lead to a significant increase in infection. 
Our data indicate the need for future studies on the application 
of petroleum jelly to help stem bleeds from injuries in contact 
sports or to a wound after minor surgery. Another area of clini-
cal interest is afibrinogenemia, since the lack of fibrin film for-
mation in this disease may lead to increased risk of persistent 
infections from minor dermal lesions (Supplemental Figure 9). 
As a corollary, an engineered fibrin film would be expected to 
improve recovery from minor and major injuries and reduce the 
probability of severe infection.
Our findings of the extraordinary formation of a protective 
fibrin film on the blood clot exterior reveal a mechanism in hemo-
stasis that helps retain blood cells and control microbial infection. 
Clot film formation appears an important physiological process 
that should be exploited in the future to improve recovery and 
healing from minor and major injuries.
Methods
Materials. Human plasma fibrinogen, plasminogen-depleted (Cal-
biochem), was further purified by immunoaffinity chromatography 
(IF-1 mAb, 10 mg; Kamiya Biomedical) as previously described (35) 
to eliminate FXIII (36). Alexa Fluor 488– or Alexa Fluor 594–fibrin-
ogen (Invitrogen) was reconstituted to 2.5 mg/ml, human thrombin 
(Calbiochem) was reconstituted to 250 U/ml; and tPA (Pathway Diag-
nostics) and Glu-plasminogen (Enzyme Research Laboratories) were 
diluted in 0.05 M Tris-Base, 0.1 M NaCl, pH 7.4 (TBS) to 1 mg/ml and 
990 μg/ml, respectively, and stored at –80°C. Human FXIII-A2B2 was 
isolated from contaminating albumin and glucose from Fibrogammin 
P (Zedira) by Sepharose-6B gel filtration as described previously (12). 
FXIII was diluted in TBS to 110 μg/ml and stored at –80°C. All other 
chemicals were obtained from Sigma-Aldrich unless stated otherwise.
Whole blood. Samples of free-flowing blood were collected from 
the antecubital vein of healthy volunteers. Blood was collected on 
0.109 M sodium citrate and was used within 4 hours.
PPP and PRP. Free-flowing blood was obtained from the antecu-
bital vein of 24 healthy volunteers as described above. The blood was 
centrifuged at 2,400 g for 20 minutes for PPP or at 200 g for 10 minutes 
for PRP. PPP and PRP from 6 individuals were used to form clots for film 
formation comparison. PPP samples from 24 volunteers were pooled, 
aliquoted, and snap-frozen in liquid nitrogen and stored at –80˚C.
Purification of γA/γA and γA/γ′ fibrinogen. γA/γA and γA/γ′ fibrino-
gens were isolated as previously described (8, 37, 38). In short, the vari-
ants were separated using a DE-52 column on an ÄKTA Avant 25 (GE 
Healthcare). Fibrinogen was dissolved in 39 mM Tris, 65 mM H3PO4, 
0.5 mM PMSF, 1 mM benzamidine, and 5 mM ε-aminocaproic acid, pH 
8.6. Samples were eluted using a concave gradient from 0% to 100% 
over 13 column volumes (with increments of 5% over the first 6 and 
increments of 10% over the next 7 column volumes) of 500 mM Tris, 
650 mM H3PO4, 0.5 mM PMSF, 1 mM benzamidine, and 5 mM ε-ami-
nocaproic acid, pH 4.2. The fibrinogens were concentrated and dialyzed 
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Confocal time series formation/lysis. To investigate film forma-
tion, the reaction mixture was produced as above for both plasma 
and purified fibrinogen. A 27-μl drop of this mixture was placed into 
the center of a well of an uncoated 8-well Ibidi slide. 2 μl thrombin 
(0.5 U/ml) or tissue factor (5 pM) was added to the drop, which was 
immediately observed by LSCM. The effects of preventing polym-
erization were investigated by preincubating fibrinogen (1 mg/ml) 
or plasma with GPRP (5 mM) for 20 minutes. Thrombin (3 μl, 0.5 
U/ml) was added to the drop, which was immediately observed by 
LSCM using a 40× oil immersion objective lens with 29 × 0.7–μm 
Z-stacks every 60 seconds.
To investigate fibrinolysis, clots were formed as described above. 
After film formation, 5 μl tPA (85 ng/ml) was added to plasma clots, 
and 5 μl plasminogen (25 μg/ml) and tPA (85 ng/ml) was added to 
purified clots. The clot was immediately observed by LSCM. For-
mation and lysis were observed by LSCM using a 40× oil immersion 
objective lens. 29 × 0.7–μm Z-stacks were obtained every 60 seconds. 
3D videos were created from the Z-stacks.
Preventing film formation: oil, Tween-20, petroleum jelly. The reac-
tion mixture was made up for plasma as mentioned above for reac-
tions with oil or petroleum jelly. For oil experiments, mineral oil was 
carefully placed around the drop to fill the confocal well before clot-
ting, to eliminate the air-liquid interface before clotting was initiated. 
For petroleum jelly experiments, 27 μl of reaction mixture was injected 
into a small ball of petroleum jelly that had been placed in the middle 
of the well of a slide. For reactions with Tween-20, the reaction mix 
was incubated with 0.1% Tween-20 before clotting. Using a pipette, 
thrombin (0.5 U/ml) was added to the reaction mixture to initiate clot-
ting. The slide was transferred to a humidity chamber for 4 hours at 
room temperature. Imaging was performed using an inverted Zeiss 
LSM880 microscope with a 40× oil immersion objective lens. Each 
fibrin clot was prepared in duplicate, 4 images were taken of each sam-
ple, and Z-stacks were combined to form 3D images.
Film thickness. The thickness of the film was measured on con-
focal images 60 times per image using ImageJ (version 2.0, NIH), 
and the average thickness for each image was used to compare 
among conditions.
Fluorescence measurements. To quantify film fluorescence, an out-
line was drawn around the film on each focal plane. Area, integrat-
ed density, and 3 adjacent background readings were made using 
ImageJ. Corrected film fluorescence was calculated as follows: inte-
grated density – (area selected × mean fluorescence of background 
readings). This was calculated for each focal plane. The average of 
the corrected film fluorescence of each focal plane was taken and was 
divided by 10,000 arbitrarily to simplify the numbers, and was called 
MSF. To validate this method, measurements of film thickness from 
confocal images of 72 separate samples were taken. Sixty measure-
ments of film thickness were taken per image using ImageJ, and the 
average thickness for each image was correlated with MSF taken from 
the same image (Supplemental Figure 10B).
Film peel. Clots were generated by spreading 100 μl plasma with or 
without 1,3,4,5-tetramethyl-2-[(2-oxopropyl)thio]imidazolium chlo-
ride (T101, FXIII inhibitor, 1 mM; Zedira) or purified fibrinogen (1 mg/
ml) with or without FXIII (3.7 μg/ml) into an approximately 2 × 2–cm 
square on coverslips. 10 μl of activation mixture (human thrombin, 0.5 
U/ml and CaCl2, 5 mM) was added to initiate clotting. After 4 hours a 
hypodermic needle was used to peel the film away from the surface 
LSCM; whole blood, plasma, and purified fibrinogen. Reaction mix-
tures were prepared by diluting whole blood or plasma by half with 
saline or TBS, respectively, and spiked with 25 μg/ml Alexa Fluor 594– 
or Alexa Fluor 488–fibrinogen, respectively, and 5 mM CaCl2. Human 
thrombin (0.5 U/ml) or 5 pM tissue factor was added to initiate clotting. 
Purified fibrinogen (1 mg/ml) was spiked with 25 μg/ml Alexa Fluor 
488–fibrinogen, with or without FXIII (3.7 μg/ml) and 5 mM CaCl2. 0.5 
U/ml human thrombin was added to initiate clotting. Immediately after 
the initiation of clotting, a 30-μl drop of the mixture was transferred to 
the center of the well of an uncoated 8-well Ibidi slide (Ibidi GmbH), 
and the slide was transferred to a dark humidity chamber for 4 hours 
at room temperature. Imaging was performed using an inverted Zeiss 
LSM880 microscope with a 40× oil immersion objective lens. Fibrin 
clots were prepared in duplicate, 4 images were taken at the air-liquid 
interface for each clot (Supplemental Figure 10A), and Z-stacks (20 μm, 
30 slices) were combined to form 3D images (ZEN 2.1 black, Zeiss).
Conditions: thrombin, calcium, fibrinogen concentration, reptilase, 
temperature, platelets, fibrinogen variants. LSCM and SEM were carried 
out as above, but with changes to some of the conditions. Experiments 
were carried out in which clotting was initiated with different throm-
bin (final concentrations: 0.1, 0.5, 1, 10 U/ml), CaCl2 (0, 5, 10, 20 mM), 
and fibrinogen concentrations (0.05, 0.5, 1, 2.5 mg/ml) in a purified 
system. Clotting was also initiated with reptilase (2.4 U/ml; Diagnos-
tica Stago) to investigate the effects of only cleaving fibrinopeptide A 
compared with thrombin (0.5 U/ml).
The effects of temperature were investigated by incubating the 
reaction mix at different temperatures (21°C, 31.5°C, 37°C) before 
and throughout clotting. Average skin temperature was determined as 
31.5°C using a contact thermometer on the forearm and hand. Imme-
diately after clotting initiation, a 30-μl drop of the reaction mixture 
was transferred into the center of the well of an uncoated 8-well Ibidi 
slide, and the slide was transferred to a dark humidity chamber in an 
incubator at the appropriate temperature for 4 hours.
The effects of platelets on film formation were studied by com-
paring film formation in PPP and PRP from 6 healthy volunteers. 
Reaction mixtures were prepared by diluting PPP or PRP by half with 
saline and spiked with 25 μg/ml Alexa Fluor 594–fibrinogen and 5 mM 
CaCl2. Tissue factor (5 pM) was added to initiate clotting.
The effects of fibrinogen variants were investigated with purified 
γA/γA or γA/γ′, γ3x mutant, or α220 or α390 mutant (each at 2.94 μM).
Fibrin(ogen)-binding Affimers for imaging the film in dys- and afibrin-
ogenemia. Free-flowing blood was obtained from the antecubital vein of 
2 dysfibrinogenemia patients (FGA c.112A>G, p.R38G; FGG c.901C>T, 
p.R301C) and 3 afibrinogenemia patients (all with the FGA c.635T>G, 
p.L212X mutation) as described above. The blood was centrifuged at 
2,400 g for 20 minutes for PPP. These samples were aliquoted, snap-fro-
zen in liquid nitrogen, and stored at –80˚C. To image the plasma sam-
ples, a fibrin(ogen)-specific Affimer was isolated from an Affimer phage 
display library using a previously described screening process (10). This 
Affimer was fluorescently labeled using an Alexa Fluor 488 protein label-
ing kit (Invitrogen) according to manufacturer’s instructions. Fluores-
cently labeled Affimer was then added to normal pool plasma or patient 
plasma at 17.6 μM and incubated for 30 minutes. Clotting was initiated 
with 5 mM CaCl2 and 0.5 U/ml human thrombin, and a 30-μl drop of 
the mixture was immediately transferred to the center of the well of an 
uncoated 8-well Ibidi slide. Clots were incubated for 4 hours in a humidi-
ty chamber and were then imaged by LSCM as described above.
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the surface pressure was below 0.3 mN/m. The system was set to 
record surface pressure every second for 18 hours. The desired 
protein concentration was achieved by diluting in TBS (fibrino-
gen, 1, 5, 20, 30, 100, 5,312 × 1013 molecules [final concentrations, 
0.00018–1 mg/ml]; fibrin 1, 5, 20, 30, 100 × 1013 molecules [final 
concentrations, 0.00018–0.019 mg/ml]), and the sample was 
injected into the subphase in one 50-μl injection with a Hamilton 
Gastight syringe (Thermo Fisher Scientific) and left for 18 hours. 
Fibrin monomers were formed by preincubating fibrinogen with 
GPRP (5 mM) overnight, followed by incubation with thrombin (0.5 
U/ml) for 2 hours. As a control a 50 μl mixture of thrombin (0.5 U/
ml) and GPRP (5 mM) was run on the trough to show that it caused 
no change in surface pressure.
Bacteria migration assay. To investigate bacteria migration, an 
assay was set up using a Boyden chamber (VWR) as shown in Figure 
5A. Three types of bacteria — Escherichia coli (ATCC 13706), Staphy-
lococcus epidermidis (ATCC 12228), and Staphylococcus aureus (ATCC 
29247) — commonly found in the natural skin flora were transformed 
with pSELECT-zeo plasmid (Invivogen) to provide resistance to anti-
biotic Zeocin. A single colony was picked for each bacterium and was 
grown up overnight (3.6 × 108 to 8.5 × 108 cells/ml) in nutrient broth 
containing Zeocin (25 μg/ml, Sigma-Aldrich). Three clots for each 
strain of bacteria were formed in a Boyden chamber (0.8-μm pores, 
Millipore), 2 normal (1 mg/ml fibrinogen, 5 mM CaCl2 , 0.5 U/ml 
thrombin) and 1 in the presence of Tween-20 (0.1%), and left over-
night in a humidity chamber at room temperature. The next day the 
film on one of the normal clots for each bacterium was perforated 
by running a hypodermic needle across the surface of the clot. Each 
bacterium was fluorescently labeled with BacLight green following 
the manufacturer’s instructions (Thermo Fisher Scientific). The bac-
teria were then spun down and resuspended in 50% nutrient broth to 
remove any unused label and were checked for fluorescence levels. 
Zeocin (25 μg/ml) was added to SOC media (Thermo Fisher Scientif-
ic), and 1 ml was added to each well of the plate. Each clot was placed 
in the well, and 300 μl of labeled bacteria was added in the chamber 
on top of each clot. SOC media (50 μl) was taken from each well and 
replaced with fresh SOC media every 2 hours for 48 hours and mea-
sured for fluorescence. The time to the first bacteria breaking through 
the clots was defined as when fluorescence reached a level greater 
than 2% of the added fluorescent bacteria.
Ex vivo WT and fibrinogen-deficient mouse blood clots. C57BL/6 
and fibrinogen-deficient mice (C57BL/6 background; in-house) (39), 
aged 9–14 weeks and weighing 19–30 g, were used for all experiments 
(n = 4). Male and female mice were used in equal numbers. The mice 
were anesthetized with isoflurane and bled through the inferior vena 
cava on 0.109 M sodium citrate before being euthanized. Whole blood 
clots from WT and fibrinogen-deficient mice were prepared for SEM 
as described above, but clotting was initiated with mouse thrombin 
(0.5 U/ml). Each clot was formed in duplicate and imaged in 5 areas at 
5 different magnifications (2,500×, 5,000×, 10,000×, 25,000×, and 
50,000×) using a Hitachi SU8230 high-performance CFE SEM.
In vivo mouse dermal punctures. C57BL/6 (in-house) or BALB/cJRj 
mice (Janvier Labs), aged 9–14 weeks and weighing 19–30 g, were 
used for all experiments. Male and female mice were used in equal 
numbers. The mice were anesthetized with isoflurane, and the abdo-
men was shaved and waxed. Six puncture wounds were created using 
a 2-mm biopsy punch (World Precision Instruments Ltd.) and were 
of the clot (Figure 2A). The film was either reduced and run on SDS-
PAGE or was stretched over a coverslip exposing either the interior 
surface or exterior surface of the film and was prepped for SEM.
SDS-PAGE and Western blot analysis. Clots were made using 
plasma by the addition of thrombin (0.5 U/ml) and CaCl2 (5 mM), 
with and without FXIII inhibitor T101 (1 mM). The fibrin film was 
removed from each clot and reduced by the addition of NuPAGE 
sample reducing agent (100 mM DTT) and heating at 95°C for 15 
minutes. Fibrin samples were prepared by the formation of a clot 
with IF-1 fibrinogen (1 mg/ml), addition of thrombin and CaCl2, and 
reduction as described above. FXIII-, BSA-, and IF-1–purified fibrin-
ogen samples were reduced in a similar way and run alongside the 
films to help identify bands in the gel, and as controls for the blots. 
Protein concentrations were determined using NanoDrop to load 2 
μg of each protein sample on 2 identical 4%–12% NuPAGE Bis-Tris 
gels. After running, one gel was stained using GelCode Blue Safe 
Protein Stain (Thermo Fisher Scientific), and one was transferred to 
a PVDF membrane (Thermo Fisher Scientific). The membrane was 
blocked overnight using 4% skim milk in 50 mM Tris, 150 mM NaCl, 
0.1% Tween-20. Polyclonal rabbit anti–human fibrinogen antibody 
(A0080; Dako) was added to the blot in blocking buffer and detect-
ed using goat anti-rabbit HRP secondary antibody (P0448; Dako). 
Signal was detected using SuperSignal West Pico Chemilumines-
cent Substrate (Thermo Fisher Scientific).
AFM sample preparation. Samples for AFM mechanical measure-
ments and imaging were prepared from normal pool plasma with a 1:2 
final dilution. Briefly, plasma was mixed with an activation mixture of 
CaCl2 (5 mM) and thrombin (0.5 U/ml) and placed onto a 34-mm-di-
ameter tissue culture dish (TPP) with the plasma mixture covering 
a 10 × 10–mm square. For samples with T101, a final concentration 
of 1 mM was added to the mixture. Samples were then placed into a 
humidity chamber and allowed to clot for 1 hour. Samples were hydrat-
ed with 3–5 ml of 50-mM Tris, 100 mM NaCl, and placed on the AFM 
sample stage. Imaging and force measurements were performed on 
a JPK Instruments NanoWizard 4 and a Zeiss AxioObserver D1 in qi 
mode with 10-nm-radius AFM probes (CB3, qp-BioAC, Nanosensors). 
All measurements were done in triplicate over a 15 × 15–μm square.
Langmuir-Blodgett trough. Surface tension measurements were 
used to determine fibrinogen and fibrin adsorption at the air-liq-
uid interface. Measurements were performed with an extra small 
KSV NIMA double-barrier Langmuir-Blodgett trough (203 × 50 × 
1.2 mm) with surface pressure sensor, based on the Wilhelmy meth-
od, with a Whatman CHR1 chromatography paper plate (perimeter, 
20.6 mm; accuracy in surface pressure, 0.01 μN/ml; KSV NIMA, 
Biolin Scientific). Because adsorption measurements are sensitive 
to the presence of impurities, extreme care was taken to ensure that 
all materials and instruments used in this study were clean. The 
trough and barriers were cleaned with methanol and rinsed with 
deionized water before each run. A new Wilhelmy plate was used 
for each run. Due to the duration of the experiment, the trough 
was maintained in a dust and draught exclusion cabinet through-
out the measurements to minimize the presence of impurities from 
the atmosphere. A humid atmosphere was maintained by putting a 
trough of water in the enclosing box. The subphase was composed 
of 30 ml of 0.2 μm filtered TBS pH 7.4 at room temperature. The 
surface was checked prior to each measurement to ensure that it 
was clean by moving the barriers to the center and confirm that 
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n = 4). All animals were subsequently infected with 2 μl bioluminescent 
P. aeruginosa suspension deposited on top of the clots. Mice were then 
anesthetized and imaged to check that the same amount of bacteria 
was added to each mouse and then anesthetized again at 4, 8, and 12 
hours after bacterial infection to allow for data acquisition using a 3D 
IVIS Spectrum In Vivo Imaging System (PerkinElmer) and analysis 
using Living Image software (PerkinElmer). Differences in appearance 
between mice with film and without film in Figure 7 are due to the oil 
used to prevent film formation being transferred to the fur of the mice.
Determination of bacterial CFU. In order to study bacterial growth 
and dissemination, the skin around the wound was harvested from 
sacrificed animals at the end of the experiment (12 hours). The tissues 
were mechanically homogenized using 1.4-mm ceramic beads (QIA-
GEN) and a MagNA Lyser (Roche), and serial dilutions were subse-
quently plated on TH agar plates overnight at 37°C in order to enumer-
ate the bacterial CFU present in the samples.
Statistics. All statistical analyzes were performed with GraphPad 
Prism 7. All experiments were repeated at least 3 times. Data were test-
ed for normality using Shapiro-Wilk normality test. Data are present-
ed as mean and SD for parametric data and mean and IQR for non-
parametric data. For the comparisons of 2 groups, 2-tailed unpaired t 
test was performed. For comparisons between multiple groups, either 
1-way ANOVA followed by Dunnett’s multiple comparisons test or 
2-way ANOVA for parametric data was performed, and Kruskal-Wallis 
test was performed for nonparametric data. A P value less than 0.05 
was considered significant.
Study approval. Ethical approval for blood taking was obtained 
from the University of Leeds Medical School or the University Hospi-
tals of Geneva and Faculty of Medicine review board. Written informed 
consent was received from each patient and volunteer prior to inclu-
sion in the study in accordance with the Declaration of Helsinki. Writ-
ten informed consent was provided by the patient for the photograph 
shown in Supplemental Figure 9. All mouse experiments were conduct-
ed according to institutional guidelines and were authorized by either 
the University of Leeds Ethics Committee, in accordance with Home 
Office UK Animals (Scientific Procedures) Act 1986, or the Malmö-
Lund Animal Care Ethics Committee, Sweden (entry no. M89-16).
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